(COV) Covivio - Overview

Sector: Real Estate | Industry: REIT - Diversified | Exchange: PA (France) | Market Cap: 6.275m EUR | Total Return: 34.8% in 12m

Hotels, Offices, Residences, Spaces
Total Rating 53
Safety 61
Buy Signal -0.08
REIT - Diversified
Industry Rotation: -5.1
Market Cap: 7.32B
Avg Turnover: 10.3M EUR
ATR: 3.03%
Peers RS (IBD): 67.3
Risk 5d forecast
Volatility30.4%
Rel. Tail Risk-4.75%
Reward TTM
Sharpe Ratio0.96
Alpha16.35
Character TTM
Beta0.227
Beta Downside-0.261
Drawdowns 3y
Max DD26.95%
CAGR/Max DD0.30

Warnings

Altman Z'' 0.07 < 1.0 - financial distress zone

Tailwinds

No distinct edge detected

Description: COV Covivio

Covivio (COV) is a European real estate company. It operates across various segments, including offices, hotels, and residential properties. This diversified approach is common among large real estate investment trusts (REITs) seeking stable income streams.

The company focuses on creating adaptable urban spaces, aligning with the evolving demands for integrated work, travel, and living environments. Real estate companies often aim to develop properties that cater to mixed-use trends, enhancing their appeal and value.

Covivio emphasizes sustainable relationships and responsible real estate operations, addressing stakeholders from customers to future generations. For further in-depth analysis, consider exploring ValueRay.

Headlines to Watch Out For
  • European real estate demand impacts rental income
  • Interest rate fluctuations affect financing costs
  • Regulatory changes influence property development
  • Economic downturns reduce hotel and office occupancy
Piotroski VR‑10 (Strict) 5.0
Net Income: 806.9m TTM > 0 and > 6% of Revenue
FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.16 > 1.0
NWC/Revenue: -71.82% < 20% (prev 6.74%; Δ -78.56% < -1%)
CFO/TA 0.06 > 3% & CFO 1.56b > Net Income 806.9m
Net Debt (9.43b) to EBITDA (1.66b): 5.67 < 3
Current Ratio: 0.44 > 1.5 & < 3
Outstanding Shares: last quarter (110.8m) vs 12m ago 10.65% < -2%
Gross Margin: 63.87% > 18% (prev 0.73%; Δ 6.31k% > 0.5%)
Asset Turnover: 9.82% > 50% (prev 11.19%; Δ -1.37% > 0%)
Interest Coverage Ratio: 38.66 > 6 (EBITDA TTM 1.66b / Interest Expense TTM 27.4m)
Altman Z'' 0.07
A: -0.06 (Total Current Assets 1.21b - Total Current Liabilities 2.77b) / Total Assets 25.34b
B: 0.03 (Retained Earnings 738.7m / Total Assets 25.34b)
C: 0.05 (EBIT TTM 1.06b / Avg Total Assets 22.23b)
D: 0.06 (Book Value of Equity 738.7m / Total Liabilities 12.69b)
Altman-Z'' Score: 0.07 = B
Beneish M -3.35
DSRI: 0.46 (Receivables 226.5m/481.4m, Revenue 2.18b/2.14b)
GMI: 1.15 (GM 63.87% / 73.36%)
AQI: 1.01 (AQ_t 0.87 / AQ_t-1 0.87)
SGI: 1.02 (Revenue 2.18b / 2.14b)
TATA: -0.03 (NI 806.9m - CFO 1.56b) / TA 25.34b)
Beneish M-Score: -3.35 (Cap -4..+1) = AA
What is the price of COV shares? As of April 10, 2026, the stock is trading at EUR 56.75 with a total of 182,774 shares traded.
Over the past week, the price has changed by +5.58%, over one month by +3.78%, over three months by +7.81% and over the past year by +34.84%.
Is COV a buy, sell or hold? Covivio has no consensus analysts rating.
What are the forecasts/targets for the COV price?
Analysts Target Price - -
Covivio (COV) - Fundamental Data Overview as of 10 April 2026
Market Cap USD = 7.32b (6.28b EUR * 1.1659 EUR.USD)
P/E Trailing = 8.5445
P/E Forward = 10.7875
P/S = 5.4754
P/B = 0.6912
P/EG = 24.6239
Revenue TTM = 2.18b EUR
EBIT TTM = 1.06b EUR
EBITDA TTM = 1.66b EUR
Long Term Debt = 8.66b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.98b EUR (from shortLongTermDebt, last quarter)
Debt = 10.63b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.43b EUR (from netDebt column, last quarter)
Enterprise Value = 15.70b EUR (6.28b + Debt 10.63b - CCE 1.21b)
Interest Coverage Ratio = 38.66 (Ebit TTM 1.06b / Interest Expense TTM 27.4m)
EV/FCF = 33.78x (Enterprise Value 15.70b / FCF TTM 464.8m)
FCF Yield = 2.96% (FCF TTM 464.8m / Enterprise Value 15.70b)
FCF Margin = 21.30% (FCF TTM 464.8m / Revenue TTM 2.18b)
Net Margin = 36.97% (Net Income TTM 806.9m / Revenue TTM 2.18b)
Gross Margin = 63.87% ((Revenue TTM 2.18b - Cost of Revenue TTM 788.6m) / Revenue TTM)
Gross Margin QoQ = 70.12% (prev 62.50%)
Tobins Q-Ratio = 0.62 (Enterprise Value 15.70b / Total Assets 25.34b)
Interest Expense / Debt = 0.26% (Interest Expense 27.4m / Debt 10.63b)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 794.4m (EBIT 1.06b * (1 - 25.00%))
Current Ratio = 0.44 (Total Current Assets 1.21b / Total Current Liabilities 2.77b)
Debt / Equity = 1.23 (Debt 10.63b / totalStockholderEquity, last quarter 8.61b)
Debt / EBITDA = 5.67 (Net Debt 9.43b / EBITDA 1.66b)
Debt / FCF = 20.28 (Net Debt 9.43b / FCF TTM 464.8m)
Total Stockholder Equity = 8.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.63% (Net Income 806.9m / Total Assets 25.34b)
RoE = 9.72% (Net Income TTM 806.9m / Total Stockholder Equity 8.30b)
RoCE = 6.25% (EBIT 1.06b / Capital Employed (Equity 8.30b + L.T.Debt 8.66b))
RoIC = 4.17% (NOPAT 794.4m / Invested Capital 19.07b)
WACC = 2.64% (E(6.28b)/V(16.91b) * Re(6.78%) + D(10.63b)/V(16.91b) * Rd(0.26%) * (1-Tc(0.25)))
Discount Rate = 6.78% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 5.19%
[DCF] Terminal Value 88.22% ; FCFF base≈431.5m ; Y1≈519.6m ; Y5≈838.7m
[DCF] Fair Price = 135.1 (EV 24.39b - Net Debt 9.43b = Equity 14.97b / Shares 110.8m; r=6.0% [WACC]; 5y FCF grow 21.81% → 3.0% )
EPS Correlation: -8.18 | EPS CAGR: -27.95% | SUE: 0.0 | # QB: 0
Revenue Correlation: 41.42 | Revenue CAGR: 16.03% | SUE: 0.22 | # QB: 0
EPS current Year (2026-12-31): EPS=4.86 | Chg7d=-0.036 | Chg30d=-0.024 | Revisions Net=+0 | Growth EPS=+6.2% | Growth Revenue=+5.4%
EPS next Year (2027-12-31): EPS=5.04 | Chg7d=+0.013 | Chg30d=+0.026 | Revisions Net=+1 | Growth EPS=+3.7% | Growth Revenue=+12.0%
[Growth] Implied Growth Rate = -3.8% (Discount Rate 7.9% - Earnings Yield 11.7%)
[Growth] Growth Spread = +15.8% (Analyst 12.0% - Implied -3.8%)